Differences in utilization, complications, and mortality after cancer surgery by HIV status among Medicaid beneficiaries from 2001-2021

This study of Medicaid beneficiaries from 2001 to 2021 found that while people with HIV undergoing cancer surgery experience higher healthcare utilization and longer hospital stays compared to those without HIV, they have similar short-term complications but face significantly elevated long-term mortality risks, particularly beyond 90 days post-surgery.

The Gist

Imagine the healthcare system as a massive, bustling highway system. On this road, millions of people are driving toward a destination: recovery after cancer surgery. For a long time, there was a fear that drivers with a specific condition (HIV) might be more likely to crash, get lost, or never reach their destination compared to drivers without that condition.

This study looked at a huge map of this highway, tracking nearly 200,000 drivers (Medicaid patients) over 20 years (2001–2021). The researchers wanted to see if having HIV changed the journey after cancer surgery.

Here is what they found, broken down into simple stories:

1. The "Heavy Luggage" Effect (Hospital Stays)

Think of a hospital stay like packing for a trip. The study found that people with HIV (PWH) were more likely to take the "heavy luggage" route. They stayed in the hospital longer than people without HIV.

• The Analogy: If a standard surgery is like a weekend getaway, people with HIV were staying for an extra few days, almost like they needed a longer vacation to recover.
• The Numbers: On average, they stayed about 3 extra days in the hospital and had more visits to the Emergency Room (ED) afterward. It's as if their bodies needed a little more "pit stop" time to get back on track.

2. The "Smooth Start" (Short-Term Safety)

Here is the good news: Once the surgery was done, the immediate journey was surprisingly safe for everyone.

• The Analogy: Imagine two cars leaving a race track. Even though one car had a heavier engine (HIV), both cars crossed the finish line (30 days later) without blowing a tire or crashing.
• The Findings: There was no difference in surgical infections, readmissions, or deaths within the first month. This suggests that surgeons and hospitals are doing a great job treating people with HIV just as well as anyone else, following the same playbook.

3. The "Long Haul" Challenge (Long-Term Survival)

While the immediate trip was smooth, the long road trip showed some differences.

• The Analogy: Think of the first 90 days as the first leg of a flight. Everyone made it. But when looking at the full 5-year journey, the drivers with HIV were slightly more likely to run out of fuel or face a breakdown later on.
• The Findings: People with HIV had a higher risk of dying within 1 to 5 years after surgery compared to those without HIV. However, there was a bright spot: In the last decade (since 2012), when modern HIV medications became standard for everyone, this gap started to shrink. It's like upgrading the car's engine with better technology, making the long journey much safer.

4. The "Treat-All" Era

The study highlights a turning point in time. Before 2012, the gap in long-term survival was wider. After 2012, when doctors started treating all HIV patients immediately with medication (the "treat-all" era), the outcomes got much better.

• The Metaphor: It's like realizing that if you fix the engine before the long trip starts, the car runs much smoother for years.

The Bottom Line

This research tells us two main things:

1. Don't Worry About the Surgery: Hospitals are treating people with HIV safely. The surgery itself isn't the problem; the immediate recovery is just as good as for anyone else.
2. Keep the Engine Running: The challenge isn't the surgery; it's the long-term health after. People with HIV need extra support and monitoring on the "long road" after they leave the hospital to ensure they stay healthy for years to come.

In short: The surgery is a safe ride for everyone, but people with HIV might need a few more pit stops along the way and a little extra care to ensure they finish the whole race.

Technical Summary

Technical Summary: Differences in Utilization, Complications, and Mortality After Cancer Surgery by HIV Status Among Medicaid Beneficiaries (2001–2021)

1. Problem Statement

People with HIV (PWH) historically face higher cancer-specific mortality and potentially worse surgical outcomes compared to people without HIV (PWoH). However, existing literature on this disparity largely predates the widespread adoption of the "treat-all" antiretroviral therapy (ART) era (post-2012). There is a critical need to understand whether these disparities persist in the modern treatment landscape, specifically within the Medicaid population, which often represents a vulnerable, low-income demographic with complex comorbidities. This study addresses the gap in knowledge regarding postoperative utilization, complications, and mortality for PWH undergoing cancer surgery in the contemporary ART era.

2. Methodology

• Study Design & Population: A retrospective cohort study analyzing Medicaid beneficiaries across 26 states and Washington, D.C., from 2001 to 2021.
• Cohort Selection: The study identified adults with continuous Medicaid enrollment for at least 6 months pre-surgery and 3 months post-surgery. The cohort included those undergoing their first inpatient or outpatient surgery for 12 specific cancer types: anal, bladder, breast, colorectal, female genitourinary, gastroesophageal, head and neck, kidney, liver, lung, ovarian, and pancreatic.
• Exposure: HIV status (PWH vs. PWoH).
• Outcomes Measured:
  • Utilization: Length of stay (LOS), extended hospital stays, emergency department (ED) visits, and readmissions (7-day and 30-day, overall and unplanned).
  • Complications: Surgical site infections (SSI).
  • Mortality: 30-day, 90-day, 1-year, and 5-year mortality.
• Statistical Analysis:
  • Models: Linear regression (for continuous outcomes like LOS), logistic regression (for binary outcomes like readmission/SSI), and Cox proportional hazards models (for time-to-event outcomes like mortality).
  • Adjustments: Models were adjusted for demographics, comorbidities, cancer type, surgical setting/risk, metastasis status, and preoperative treatments (radiation/chemotherapy).
  • Stratification: Analyses were stratified by surgical setting (inpatient vs. outpatient) and cancer type, with specific attention to the "treat-all" ART era (2012–2021).

3. Key Contributions

• Temporal Scope: This is one of the largest and most comprehensive studies to date covering a 20-year period, explicitly capturing the transition into the modern "treat-all" ART era.
• Population Specificity: By focusing on Medicaid beneficiaries, the study provides insights into outcomes for a socioeconomically disadvantaged population where HIV and cancer disparities are often most pronounced.
• Granular Outcome Analysis: Unlike previous studies that may have focused solely on mortality, this research provides a multi-dimensional view including resource utilization (LOS, ED use) and both short-term (30-day) and long-term (5-year) survival metrics.

4. Key Results

• Demographics & Utilization:
  • Among 198,535 beneficiaries, 4,199 (2.1%) were PWH.
  • PWH were significantly more likely to undergo inpatient procedures (72.6% vs. 56.4% for PWoH).
  • Increased Utilization: PWH experienced significantly longer hospital stays. The adjusted mean difference (aMD) was 0.79 days for standard LOS and 2.76 days for extended stays. PWH also had higher ED utilization (0.82 vs. 0.55 visits per 90 days).
• Short-Term Complications:
  • Contrary to historical fears, there were no significant differences between PWH and PWoH regarding 7-day or 30-day readmissions, surgical site infections (SSI), or 30-day mortality.
• Mortality Disparities:
  • 90-Day Mortality: PWH had higher 90-day mortality (3.2% vs. 1.8%; aOR = 1.31). However, this disparity was notably attenuated during the treat-all ART era (2012–2021).
  • Long-Term Mortality: PWH faced a significantly elevated hazard for long-term death.
    • 1-Year Mortality: aHR = 1.31 (95% CI: 1.17–1.46).
    • 5-Year Mortality: aHR = 1.22 (95% CI: 1.14–1.31).
  • Cancer-Specific Findings: The mortality risk was particularly pronounced for colorectal cancer, with a 1-year aHR of 1.53 and a 5-year aHR of 1.32.

5. Significance and Implications

• Validation of Current Guidelines: The finding that PWH do not experience higher rates of short-term complications (SSI, readmission) or 30-day mortality supports current clinical guidelines recommending that PWH receive standard cancer care without withholding surgery due to HIV status.
• Resource Allocation: The data indicates that PWH require more postoperative resources (longer LOS, more ED visits), suggesting a need for enhanced care coordination and discharge planning for this population to manage the increased utilization burden.
• Unresolved Long-Term Disparities: While short-term surgical safety is comparable, the persistent elevation in 1-year and 5-year mortality suggests that factors beyond the immediate surgical event—such as post-operative recovery, adherence to adjuvant therapy, or underlying HIV-related comorbidities—drive long-term survival gaps.
• Future Directions: The study highlights an urgent need to investigate the specific mechanisms driving long-term mortality in PWH, particularly for colorectal cancer, to develop targeted interventions that improve long-term survival outcomes in the treat-all era.